Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains

This publication has 41 references indexed in Scilit:

• AAV serotype 2 vectors preferentially integrate into active genes in mice
  Nature Genetics, 2003
• Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors
  Blood, 2003
• Second Child in French Trial Is Found to Have Leukemia
  Science, 2003
• Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice*
  Physiological Genomics, 2002
• Gene Therapy a Suspect in Leukemia-like Disease
  Science, 2002
• The Early IL-4 Response toLeishmania majorand the Resulting Th2 Cell Maturation Steering Progressive Disease in BALB/c Mice Are Subject to the Control of Regulatory CD4+CD25+ T Cells
  The Journal of Immunology, 2002
• Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in Vivo
  Human Gene Therapy, 1999
• The incidence of factor VIII inhibitors in the United Kingdom, 1990‐93
  British Journal of Haematology, 1995
• Hemophilia A
  New England Journal of Medicine, 1994
• Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
  The Lancet, 1993